EAM Global Investors LLC trimmed its stake in shares of Natera Inc (NASDAQ:NTRA) by 16.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 60,375 shares of the medical research company’s stock after selling 11,590 shares during the period. EAM Global Investors LLC owned about 0.10% of Natera worth $1,445,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. State Board of Administration of Florida Retirement System purchased a new stake in shares of Natera during the second quarter valued at $200,000. Meeder Asset Management Inc. increased its position in Natera by 920.5% in the 3rd quarter. Meeder Asset Management Inc. now owns 8,399 shares of the medical research company’s stock worth $200,000 after purchasing an additional 7,576 shares during the last quarter. Paradigm Capital Management Inc. NY acquired a new position in Natera in the 2nd quarter worth about $207,000. Cubist Systematic Strategies LLC acquired a new position in Natera in the 2nd quarter worth about $252,000. Finally, Woodmont Investment Counsel LLC acquired a new position in Natera in the 2nd quarter worth about $258,000. 80.39% of the stock is owned by institutional investors and hedge funds.

In other Natera news, CEO Matthew Rabinowitz sold 403,462 shares of the firm’s stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $24.90, for a total value of $10,046,203.80. Following the completion of the sale, the chief executive officer now owns 1,701,686 shares in the company, valued at approximately $42,371,981.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Michael Burkes Brophy sold 108,108 shares of the stock in a transaction that occurred on Friday, September 14th. The stock was sold at an average price of $24.31, for a total value of $2,628,105.48. Following the completion of the transaction, the chief financial officer now directly owns 22,000 shares of the company’s stock, valued at $534,820. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 2,014,988 shares of company stock valued at $48,674,710. 13.18% of the stock is owned by corporate insiders.

NTRA opened at $16.78 on Monday. The stock has a market cap of $1.04 billion, a PE ratio of -6.99 and a beta of 2.11. Natera Inc has a 52-week low of $8.60 and a 52-week high of $29.62. The company has a quick ratio of 2.32, a current ratio of 2.44 and a debt-to-equity ratio of 1.30.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, November 8th. The medical research company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.03). Natera had a negative net margin of 58.00% and a negative return on equity of 2,569.52%. The business had revenue of $65.30 million for the quarter, compared to the consensus estimate of $66.42 million. During the same quarter in the previous year, the company earned ($0.51) EPS. Natera’s revenue for the quarter was up 16.8% compared to the same quarter last year. On average, equities research analysts forecast that Natera Inc will post -2.11 earnings per share for the current year.

Several research analysts have weighed in on NTRA shares. Piper Jaffray Companies upped their target price on Natera to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, August 9th. Craig Hallum upped their target price on Natera from $23.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, August 9th. TheStreet raised Natera from a “d” rating to a “c-” rating in a research report on Thursday, August 9th. Zacks Investment Research lowered Natera from a “buy” rating to a “hold” rating in a research report on Tuesday, August 14th. Finally, Canaccord Genuity upped their target price on Natera from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday, August 16th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Natera presently has a consensus rating of “Buy” and an average target price of $28.25.

COPYRIGHT VIOLATION NOTICE: “EAM Global Investors LLC Has $1.45 Million Stake in Natera Inc (NTRA)” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2018/11/19/eam-global-investors-llc-has-1-45-million-stake-in-natera-inc-ntra.html.

Natera Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Further Reading: How is an ETF different from a mutual fund?

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera Inc (NASDAQ:NTRA).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.